CHM 6.25% 1.7¢ chimeric therapeutics limited

Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-7

  1. 1,584 Posts.
    lightbulb Created with Sketch. 386
    This company needs way more cash though. At the current market cap they really can’t raise what they need without dilution it to nothing.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.